APA (7th ed.) Citation

Marković, F., Stjepanović, M., Rančić, M., Cekić, M., & Kontić, M. Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia. MDPI AG.

Chicago Style (17th ed.) Citation

Marković, Filip, Mihailo Stjepanović, Milan Rančić, Marina Cekić, and Milica Kontić. Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia. MDPI AG.

MLA (9th ed.) Citation

Marković, Filip, et al. Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia. MDPI AG.